Who
John W. Childs
Director
Company insider
Files Form 4 as: Director, Veradermics; Director, Biohaven; Director and 10% owner, Biohaven Pharmaceutical Holding Co; Director and 10% owner, Mattress Firm Holding; Chairman & CEO, JWC Acquisition.
In numbers
- Trades disclosed
- 149
- Buys
- 28
- Sells
- 6
- Bought
- $173.5M
- Sold
- $269.0M
- Companies
- 5
- Companies where not an officer
- 4
- First trade
- 3 Feb 2010
- Last trade
- 12 Aug 2026
- Last filed
- 14 Aug 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 12 Aug 2026filed 14 Aug 2026 | MANE VeradermicsBiotechnology | SEC FORM 4 Sold | $1.6M15,000 at $106.14 | filing |
| 12 Aug 2026filed 14 Aug 2026 | MANE VeradermicsBiotechnology | SEC FORM 4 Sold | $8.6M80,000 at $107.23 | filing |
| 12 Aug 2026filed 14 Aug 2026 | MANE VeradermicsBiotechnology | SEC FORM 4 Sold | $541K5,000 at $108.24 | filing |
| 12 Aug 2026filed 14 Aug 2026 | MANE VeradermicsBiotechnology | SEC FORM 4 Sold | $1.6M15,000 at $106.14 | filing |
| 12 Aug 2026filed 14 Aug 2026 | MANE VeradermicsBiotechnology | SEC FORM 4 Sold | $8.6M80,000 at $107.23 | filing |
| 12 Aug 2026filed 14 Aug 2026 | MANE VeradermicsBiotechnology | SEC FORM 4 Sold | $541K5,000 at $108.24 | filing |
| 28 Apr 2026filed 30 Apr 2026 | BHVN Biohavenoption or derivative · Biotechnology | SEC FORM 4 Code A | —68,693 at $0.00 | filing |
| 28 Apr 2026filed 30 Apr 2026 | BHVN Biohavenoption or derivative · Biotechnology | SEC FORM 4 Code A | —68,693 at $0.00 | filing |
| 5 Feb 2026filed 27 Feb 2026 | MANE VeradermicsBiotechnology | SEC FORM 4 Bought | $5.0M294,117 at $17.00 | filing |
| 5 Feb 2026filed 27 Feb 2026 | MANE VeradermicsBiotechnology | SEC FORM 4 Bought | $5.0M294,117 at $17.00 | filing |
| 5 Feb 2026filed 5 Feb 2026 | MANE VeradermicsBiotechnology | SEC FORM 4 Code C | —480,269 | filing |
| 5 Feb 2026filed 5 Feb 2026 | MANE VeradermicsBiotechnology | SEC FORM 4 Code C | —906,862 | filing |
| 5 Feb 2026filed 5 Feb 2026 | MANE VeradermicsBiotechnology | SEC FORM 4 Code C | —520,758 | filing |
| 5 Feb 2026filed 5 Feb 2026 | MANE Veradermicsoption or derivative · Biotechnology | SEC FORM 4 Code C | —480,269 | filing |
| 5 Feb 2026filed 5 Feb 2026 | MANE Veradermicsoption or derivative · Biotechnology | SEC FORM 4 Code C | —906,862 | filing |
| 5 Feb 2026filed 5 Feb 2026 | MANE Veradermicsoption or derivative · Biotechnology | SEC FORM 4 Code C | —520,758 | filing |
| 5 Feb 2026filed 5 Feb 2026 | MANE VeradermicsBiotechnology | SEC FORM 4 Bought | $5.0M294,117 at $17.00 | filing |
| 5 Feb 2026filed 5 Feb 2026 | MANE Veradermicsoption or derivative · Biotechnology | SEC FORM 4 Code C | —480,269 | filing |
| 5 Feb 2026filed 5 Feb 2026 | MANE Veradermicsoption or derivative · Biotechnology | SEC FORM 4 Code C | —906,862 | filing |
| 5 Feb 2026filed 5 Feb 2026 | MANE Veradermicsoption or derivative · Biotechnology | SEC FORM 4 Code C | —520,758 | filing |
News
Biohaven (BHVN) Soars 25% on FDA Drug Review, Price Target UpgradeBHVN · insidermonkey.com · 23 Oct 2026Biohaven's Troriluzole NDA Accepted For FDA Review; Decision In Q1 2027; Stock UpBHVN · rttnews.com · 22 Oct 2026Biohaven Stock Soars Nearly 30% After FDA Accepts Resubmitted Application for Rare Disease Drug VyglxiaBHVN · ibtimes.com.au · 22 Oct 2026
0 headlines in the last 90 days name John W. Childs; 3 articles from the last 14 days about the 2 companies they traded most, at most three about any one of them.